Success Metrics

Clinical Success Rate
45.5%

Based on 5 completed trials

Completion Rate
45%(5/11)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
6(55%)

Phase Distribution

Ph phase_3
3
27%
Ph phase_2
7
64%
Ph not_applicable
1
9%

Phase Distribution

0

Early Stage

7

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
7(63.6%)
Phase 3Large-scale testing
3(27.3%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

45.5%

5 of 11 finished

Non-Completion Rate

54.5%

6 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(5)
Terminated(6)

Detailed Status

Terminated6
Completed5

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
45.5%
Most Advanced
Phase 3

Trials by Phase

Phase 27 (63.6%)
Phase 33 (27.3%)
N/A1 (9.1%)

Trials by Status

completed545%
terminated655%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11